News

11/30/2021

Richmond pharma company Kaléo Acquired

New York-based Marathon Asset Management LP announced it has entered into a definitive agreement to acquire Richmond-based privately held pharmaceutical company Kaléo Inc., which is known for treating allergic anaphylaxis and opioids overdoses. The total base purchase price is approximately $310 million in cash, less certain adjustments and includes potential net revenue-based milestone payments of

11/23/2021

ATCC Announces Award from National Institute of Allergy and Infectious Diseases to Develop Research Capabilities in Infectious, Immunologic, and Allergic Diseases

ATCC, the world’s premier biological materials management and standards organization, announced that it has been awarded a seven-year, Indefinite Delivery/Indefinite Quantity (IDIQ) contract with a ceiling value of $545 million by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). With this contract, ATCC will support NIAID’s

11/19/2021

Study aiming to define acute traumatic encephalopathy (ATE) published by leading neurology journal

BrainBox HeadSmart II Study Investigators Aim to Provide Clinicians with First-Ever Biomarkers and other Functional measurements for Acute Traumatic Encephalopathy (ATE.) A clinical trial of multi-modal diagnostic/prognostic test, already underway, is published in Frontiers in Neurology/NeuroTrauma. Investigators in a major clinical trial of patients with mild traumatic brain injury (mTBI or concussion) describe for the

11/17/2021

Euclid Systems Names Key Leadership Hires and Announces Major Facility Expansion

Euclid Systems Corporation, a global leader in advanced orthokeratology and proactive myopia management, today announced two exceptional additions to its leadership team as well as the expansion of its manufacturing facility in Sterling, Virginia. The changes come at a time when Euclid’s next-generation of Ortho-K lens, Euclid MAX, is helping to combat the battle against

11/16/2021

HemoShear Therapeutics Identifies Second Novel Target to Treat NASH Through Successful Collaboration with Takeda

HemoShear Therapeutics, Inc. announced today that a second target identified utilizing the company’s REVEAL-Tx™ human disease modeling platform has been selected by Takeda Pharmaceutical Company Limited (“Takeda”) for further drug discovery activities for nonalcoholic steatohepatitis (NASH). This marks the successful completion of HemoShear’s exclusive collaboration with Takeda to discover novel targets and develop therapeutics for

11/12/2021

Richmond-based manufacturer expands operations to reduce waste, pollution and cost in the laboratory industry

Seven years after its founding as a startup business in Richmond, Grenova Inc. has moved into a new phase of development as a company. “We have been growing quite significantly,” said Ali Safavi, the founder and CEO of Grenova, which has a mission to reduce waste, pollution and costs in the global laboratory industry. Grenova,